Regenerative Secretoma of Adipose-Derived Stem Cells from Ischemic Patients by Uçkay, Ilker et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Regenerative Secretoma of Adipose-Derived Stem Cells from Ischemic
Patients
Uçkay, Ilker ; Baquié, M ; Mosseri, S ; Hervé, M P ; Bruyere-Cerdan, P
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-183931
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Uçkay, Ilker; Baquié, M; Mosseri, S; Hervé, M P; Bruyere-Cerdan, P (2019). Regenerative Secretoma of
Adipose-Derived Stem Cells from Ischemic Patients. Journal of stem cell research therapy, 9(5):1000452.
Regenerative Secretoma of Adipose-Derived Stem Cells from Ischemic
Patients
Ilker Uçkay1,2,3*#, Mathurin Baquié4#, Sébastien Mosser4, Marie-Priscille Hervé5, Pascale Bruyere-Cerdan6, Pascale Roux-Lombard6, Christine Modoux6, Lasta
Kocjancic-Curty4, Eva Rüegg7, Dimitrios Stafylakis2, Sten Ilmarjv8, Nicolo Constantino Brembilla8,9, Karl-Heinz Krause1,8 and Olivier Preynat-Seauve10
1Service of Infectious Diseases, Geneva University Hospitals, Switzerland
2Orthopedic Surgery Service, Geneva University Hospitals, Switzerland
3Infectiology, Balgrist University Hospital, Zurich, Switzerland
4Neurix SA, Avenue de la Roseraie, Geneva, Switzerland
5ECLAB, Geneva, Switzerland
6Laboratory of Immunology and Allergology, Geneva University Hospitals, Switzerland
7Service of Plastic and Aesthetic Surgery, Geneva University Hospitals, Switzerland
8Department of Pathology and Immunology, University of Geneva, Switzerland
9Service of Dermatology, Geneva University Hospitals, Switzerland
10Laboratory of Therapy and Stem Cells, Geneva University Hospitals, Switzerland
*  
#These authors contributed equally
Received date: June 10, 2019; Accepted date: June 22, 2019; Published date: July 02, 2019
Copyright: © 2019 Uçkay I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Patients with terminal ischemia often reveal chronic limb and foot ulcers with subsequent risk of infection and/or
amputation. Adipose-derived Stem Cells (ASC) may secrete angiogenic and regenerative factors. The autologous
transplantation of such cells is considered to be an attractive therapeutic strategy, but their functional properties of
ASC are influenced by many biochemical and biophysical stimuli of the microenvironment. Thus, patient-derived
ASC might not be functionally competent.
To study ASCs in ischemic disease, we have generated ASC lines from fat tissue of twelve ischemic patients.
Lines were characterized for cell surface phenotype, multipotent capacities, and production of factors involved in
wound healing. We succeeded to amplify ASC lines from all twelve patients and confirmed an ASC identity by their
ability to: (i) adhere and grow on a plastic surface in standard culture conditions; (ii) express an ASC expression
profile; (iii) differentiate in vitro into adipocytes, osteoblasts, and chondroblasts. Full transcriptome analysis of four
selected lines showed a gene expression profile compatible with healing properties including all of the functional
families involved in the wound healing process: extracellular matrix proteins, cell growth factors, pro-inflammatory
cytokines, angiogenic factors, and matrix remodeling proteins.
Our pilot study confirms that high-quality adipose stem cells can be easily derived from ischemic patients. Their
transcriptome and secretome show a regenerative profile which makes them promising candidates for autologous
therapy of chronic ulcers.
Keywords: Chronic ulcers; Chronic ischemia; Adipose stem cells;
Neovascularization; Diabetic foot infection; Secretoma; Proof-of-
principle; Laboratory
Introduction
An important number of elderly and/or diabetic patients have
advanced chronic ischemic limb disease with severe and chronic
ulcers. In the absence of correct wound healing, these ulcers become a
risk of permanent pain, infection, and amputation. Vascular surgery or
angioplasties are not always feasible, especially with a long-standing
evolution and microangiopathy. Thus, alternative strategies other than
mechanical neo-vascularization are needed. Most of the prior
innovative studies used angiogenic growth factors alone and reported a
limited efficacy [1]. This prompted many author groups to investigate
cell-based therapies. The local injection of unselected bone marrow or
peripheral blood-derived mononuclear cells was encouraging, but
often not sufficiently efficacious for complete revascularization;
probably due to the insufficient delivery of regenerative factors from a
too complex mixture of cell populations [2]. Other researchers
investigated the autologous bone marrow cell transplantation to
increase limb perfusion, with low success [3]. Mesenchymal stem cells
of adult fat tissues, called Adipose-derived Stem Cells (ASC), are
particularly attractive for the local treatment of ischemic ulcers due to
their easy accessibility with minimal invasiveness and ethical concerns,
and their ability to produce most of the healing/angiogenic factors [4].
However, the proof of feasibility in ischemic patients is almost lacking.
There is a general consensus about the potential for clinical
treatment of ischemic ulcers [5]. For ASC isolation, superficial
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subcutaneous fat is usually harvested by resection or lipoaspiration.
The viability, yield and growth characteristics of ASC are influenced by
the type of harvesting procedure, as well as by many biochemical and
biophysical stimuli in the in vivo microenvironment, such as fluid
shear stress, hydrostatic pressure, and produced factors. Mesenchymal
stem cells isolated from diabetic patients yielded dysfunctions in
oxidative stress, autophagy healing properties in mice [6] and VEGF
expression [7]. However, this observation is controversial and reports
from diabetic rats [6] or patients [7] still retain the ability to promote
wound healing. We thus describe a proof-of-principle pilot study
regarding the feasibility of amplifying ASC from patients with long-
standing ischemia and/or diabetes mellitus from various origins for a
theoretical future autologous use for chronic ulcer regeneration.
Materials and Methods
Patients and definitions
From June 2015 to April 2018, we intraoperatively sampled visually
healthy fat tissue pieces from the abdomen, limb or feet of ischemic
patients hospitalized for any orthopedic or plastic surgery. The tissues
were not infected, nor sampled from necrotic areas. The surgeons
introduced a hollow blunt-tipped cannula into the subcutaneous space
through small (1 cm) incisions or cut the pieces off. The Ethical
Committee of Geneva approved the study (NAC 14-183). We defined
chronic limb and foot ischemia on topical signs and symptoms.
ASC isolation and culture
We separated fat from the skin with scalpels, fragmented it after the
surgery in small pieces of 2 mm length, and immediately immersed it
into HBSS medium (1 volume of medium to 1 volume of fat). The
HBSS contained calcium and magnesium (Thermofisher), penicillin-
streptomycin 1 U/ml (Thermofisher). The suspension was washed
twice with 1 volume of HBSS buffer, followed by elimination of the oil
layer on the top of the suspension. After washing, the suspension was
maintained under constant agitation at 37°C for 1 hour in the presence
of collagenase NB4 0.6 U/ml (Amsbio). We then filtered the
suspension by cell strainers (100 μm) to remove residual fragments and
centrifugated at 1200 x g during 10 minutes. Then we washed the pellet
three times HBSS, prior to plating it on tissue culture flasks at a density
of 85 000 cells/cm2, using the following media: DMEM 4.5 g/l glucose
with Glutamax (Thermofisher), Fetal Calf Serum (FCS, Thermofisher)
or fibrinogen-depleted human platelet lysate 10% (Cook), penicillin/
streptomycin 1 U/ml (Thermofisher). Cells were passaged by
enzymatic dissociation using 0.5% trypsin/0.2% EDTA (Thermofisher)
(maximum for ten times).
Preparation of embryoid bodies
HS420 embryonic stem cell line was cultured on matrigel (corning)
-coated tissue culture flasks in nutristem medium (Biological
Industries) until 50% of confluency. Then, 10  M rock inhibitor
Y27632 was added in the nutristem culture media. After 24h, cells were
detached with Accutase (Thermofisher) and aggregated into spheroids
of 1000 cells through by using Aggrewell-400 (STEMCELL
technologies). 24h after aggregation, spheroids were cultured for 10
days in differentiation medium in suspension under constant agitation
in the differentiation medium. Then, spheroids were plated in
matrigel-coated dishes and cultured in adherence for an additional 11
days in differentiation medium. Differentiation medium: KnockOut
DMEM (Thermofisher), 15% KnockOut serum replacement
(Thermofisher), 2 mM L-glutamine (Sigma-Aldrich), 1% Penicillin/
Streptomycin solution (Life Technologies), 1% of MEM Non-Essential
Amino Acids Solution (Life Technologies), 0.1 mM β-mercaptoethanol
(Sigma Aldrich).
Culture of fibroblasts
Human foreskin fibroblasts (ATCC CCD-1112SK) were cultured in
DMEM culture media (Life Technologies) supplemented with 10%
fetal calf serum (Gibco) and 1% penicillin-streptomycin (Gibco). Cells
were harvested for experiments at 90% confluence.
Flow cytometry and differentiation of ASC
We analyzed the ASC phenotype with the human stem cell
verification kit (R and D Systems). Briefly, cells were incubated with
fluorochrome-labeled antibodies for 30 minutes at 4°C in binding
buffer, prior to washing them with PBS and analyzing them using the
BD AccuriTM-B6 flow cytometer (BD Biosciences). We differentiated
ASC into chondrocytes, adipocytes or osteocytes by using culture
additives and procedures according to the functional mesenchymal
stem cell verification kit (R and D Systems).
Immunocytochemistry, cytokines measurements and
microarrays
We cultured ASC on glass coverslips prior to fixation with
paraformaldehyde 0.5%; for 15 minutes at room temperature. The cells
were incubated overnight at 4°C in PBS containing 0.3% Triton X-100
and 0.5% bovine serum-albumin with primary antibodies. We
incubated the secondary anti-mouse IgM-Alexa 555 antibodies for one
hour at +4°C in the same PBS solution. The cells were again incubated
with DAPI 1 μg/ml for 10 minutes, prior to final washing and
mounting. Supernatants from ASC cultures were collected after three
days. We assessed the cytokines in culture supernatants according to
the manufacturer’s instructions, by using the human cytokine base kit
A (R and D Systems) combined with a magnetic Luminex assay (Bio-
plex 200, Biorad) and performed microarrays targeting 21 448 mRNA
chips on the extracted RNA (Complete GeneChip® Instrument System,
Affymetrix®, www.affymetrix.com). The heatmap was done on RMA
normalized data produced with the software TAC4.0.1.36
(Biosystems®) using the R package pheatmap (https://cran.r-
project.org/web/packages/pheatmap/index.html) default parameters.
The data was used without transformation.
Results
Cell lines
We derived twelve ASC lines from twelve different ischemic adults
(called iASC); eight in medium containing Fetal Calf Serum (FCS)
(Table 1); and four in medium containing Human Platelet Lysate
(HPL) (Table 2). All iASC expressed the surface profile defined by the
International Federation for Adipose Therapeutics and Science: with
positivity for CD73, CD105, CD90 and negativity for CD45, HLA-DR
and CD34 [8] (Tables 1 and 2). In the presence of appropriated media
and after two weeks, all lines differentiated on plastic towards
adipocytes (Figure 1A) expressing the specific marker FABP4 (Figure
1B). All lines also efficiently differentiated towards osteocytes (Figure
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1C) expressing osteocalcin (Figure 1D). Furthermore, the cell
compaction in the presence of a differentiation medium generated.
iASC
line
1 2 3 4 5 6 7 8
Age 92 81 74 87 84 55 57 70
Gender M F M F M M M M
Ischemi
a
Foot Limb Thigh Limb Limb Foot Calca
neus
Stump
Disease Ische
mia
Ische
mia
Ische
mia
Ische
mia
Ische
mia,
absce
ss
Ulcer
 
Ische
mia,
Hepat
itis C
Infection,
hyperten
sion
Chronic
ulcer
Yes Yes Yes Yes No Yes No Yes
Diabetic No Yes No No No No No Yes
Smoker No No No No No No Yes No
Derivati
on
2015
06 29
2015
06 29
2015
07 06
2015
07 08
2015
07 28
2015
07 28
2015
07 31
2015 08
03
Fat
collecti
on
Abdo
men
Abdo
men
Abdo
men
Abdo
men
Abdo
men
Abdo
men
Abdo
men
Abdomen
Phenoty
pe
Yes Yes Yes Yes Yes Yes Yes Yes
Differen
tiation
Adipocy
tes
Chondr
ocytes
Osteocy
tes
Yes Yes Yes Yes Yes Yes Yes Yes
Supple
ment
FCS FCS FCS FCS FCS FCS FCS FCS
Table 1: Patients characteristics for the derivation of eight iASC in
culture conditions containing FCS.
iASC line 9 10 11 12
Age 50 64 49 72
Gender F M M M
Ischemia Leg Leg Foot Foot
Disease Radiodermitis,
synoviosarcoma
 
Malformation,
Gut cancer,
alcohol
Trauma,
amputation
 
Diabetes,
chronic
ulcer,
amputation
Chronic ulcer No No No Yes
Diabetic No No No Yes
Smoker No No No No
Derivation 2018 02 21 2018 02 26 2018 03 13 2018 08 13
Fat collection Leg Foot Foot Foot
Phenotype Yes Yes Yes Yes
Differentiation
Adipocytes
Chondrocytes
Osteocytes
Yes Yes Yes Yes
Supplement HPL HPL HPL HPL
Table 2: Patients characteristics for the derivation of four iASC in
culture conditions containing HPL.
Figure 1: Differentiation of iASC 9 into adipocytes, osteocytes, and
chondrocytes iASC9 were plated at various cell densities and
cultured in two or three dimensions for several weeks in
appropriated differentiation media. (A): iASC were plated at the
density of 2.1.104 cells/cm2 and differentiated for two weeks in the
appropriated medium. After two weeks, adipocytes with oil
vacuoles within their cytoplasm were observed; (B):
Immunostaining of adipocytes after two weeks of differentiation by
using a polyclonal goat anti-mouse FABP4 antibody; (C): iASC
were plated at the density of 4.2.103 cells/cm2 and differentiated for
two weeks in the appropriated medium. After two weeks, osteocytes
were observed; (D): Immunostaining of osteocytes after two weeks
of differentiation by using a mouse anti-human osteocalcin
antibody; (E): 2.5.105 iASC were pelleted at the bottom of a sterile
tube prior to culture three weeks in the appropriated medium. After
three weeks, a chondrogenic pellet was formed and cryosectioned
for hemalum/eosin coloration; (F): Immunostaining of
chondrocytes after three weeks of differentiation by using a goat
anti-human aggrecan antibody.
Gene expression profile of iASC
To estimate the functional secretome for ischemic ulcer
regeneration, a gene expression array was performed on the four iASC
derived in clinical-grade compatible conditions (iASC9 to iASC12).
Hierarchical clustering by using the TAC4.0.1.3.6 software (Applied
Biosystems®) showed similarities among all four iASC lines (Figure 2).
This suggests a stable and reproducible gene expression profile between
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the tested lines. We then analyzed an exhaustive set of positive and
negative ASC markers.
Figure 2: Hierarchical clustering of expressed mRNA in 4 iASC. The
full transcriptoma of iASC 9-12 was analyzed by GeneChip®
Instrument System, Affymetrix®. Hierarchical clustering was
performed by the TAC4.0.1.36 applied Biosystem®.
All four lines expressed 14 positive markers and were negative for
10 leucocyte markers, confirming a robust ASC phenotype
(Supplementary Figure 1). To estimate the regenerative properties of
iASC in terms of possible ischemic ulcer regenerations, we screened in
the array the expression of genes from the most important families
involved in wound healing: cytokines, chemokines, angiogenic factors,
cell growth factors, Matrix-Metallo-Proteinases (MMP), neurotrophic
factors. To distinguish the regenerative transcriptome from a possible
background of expressed factors in the context of normal cell
physiology, controls were added in the analysis.
Embryoid Bodies (EB)-differentiated in vitro from embryonic stem
cells were used as “ non-regenerative cells ”  because contained
immature cells of the three primitive germ layers representative of
most cell types of the body and supposed to not have healing
properties. Human Foreskin Fibroblasts (HFF) were used as a
“regenerative cell” control because they are actively involved in the
healing process and produce a highly regenerative secretome making
them also candidates for cell therapy application [9]. Namely, we
investigated the pro-inflammatory properties of iASC by a complete
analysis of all cytokines. Four cytokines were found to be expressed:
IL-6, IL-11, IL-32 to 34 (Figure 3A), but only the pro-inflammatory
IL-6 was differentially expressed between EB and iASC/HFF. Screening
for chemokines yielded 9 expressed genes (Figure 3A), which are
encountered during inflammatory cell recruitment [10-15] and
angiogenesis [16]. With the exception of CCL-2, several chemokines
were expressed in iASC, but not in HFF and EB. Screening of growth
factors revealed several genes expressed (Figure 3B). The family of
Insulin Growth Factor Binding Proteins (IGFBP) was well represented
with the robust expression of IGF2BP2, IGFBP3, IGFBP4, IGFBP6, and
IGFBP7. Additionally, we observed expression of Fibroblast Growth
Factors (FGF), including FGF-2, FGF-5, and FGF-7 (or KGF/
Keratinocytes Growth factors). Most of them were higher in the four
iASC and HFF than EB and showed similar expression between the
iASC lines. Screening of angiogenic factors confirmed the presence of
6 genes such as VEGF, ANGPTL-2, ANGPTL-4, and adrenomedullin
(Figure 3C). ADM, ANGPTL-2 and VEGF-C display low expression
levels in EB and while highly and similarly expressed between the
iASC. Quantitatively, the most abundant observed mRNA expression
corresponded to matrix-metallo-proteinases (MMP), the key
remodeling factors involved in wound healing, with an expression of
MMP-1, 2, 3, 9, 14, 16, 19 (Figure 3D). Sometimes higher than EB
(MMP-1, 2, 3, 14, 19) and similar between the three iASC, this suggests
a substantial role of ASC in subcutaneous tissue remodeling (Figure
4B). Finally, screening of neurotrophic factors was performed and
found in all iASC (Figure 3E). Only neurogenin-1 (NGN1) was higher
than expressed in EBs, suggesting a potential effect of iASC in nervous
system repair.
Figure 3: mRNA expression of healing factors in iASC, EB, and
HFF. The mRNA expression of genes of functional families involved
in the healing process was analyzed from the microarray data. A
value of 6, on average, for mRNA expression, is considered to be the
cutoff of positivity as indicated by the red line. (A): Cytokines and
chemokines; (B): Cell growth factors; (C): Angiogenic factors; (D):
Matrix-Metallo-Proteinases (MMPs); (E): Neurotrophic factors.
Healing factors produced by iASC in the culture supernatant
To confirm regenerative properties at the protein level, several
cytokines and factors representative of important functional families
were measured in the medium from iASC culture by using a highly
sensitive Luminex®-based detection method. Measurements were done
in equal volumes of media three days after passage 3. Although more
variable between iASC lines, the pro-inflammatory cytokines and
chemokines IL-1, IL-6, CCL-2 and CXCL-5 were confirmed in all
supernatants (Figure 4A-4D); with a predominance of IL-6. The
immunosuppressive IL-10, as expected, was not detected (data not
shown). IL-8 (CXCL-8) was detected in all supernatants, although at
low expression at the mRNA level (data not shown). The potent growth
factor FGF-2 was also confirmed in the media (Figure 4E). Likewise,
we also detected VEGF (Figure 4F). In contrast to mRNAs, some
variability between iASC and biological replicates was noticed;
suggesting that external factors at the environmental or post-
transcriptional level add some fluctuation into the analyses.
Nevertheless, we observed less variability and quantitative
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predominance with MMPs; and a similar profile between the four
iASC (Figure 5). The quantitative predominance of MMP-2 and
MMP-3 secretion was evidenced by large amounts of a factor in culture
medium; implying the importance of ASC in tissue remodeling
processes.
Figure 4: Measurement of regenerative factors in supernatants of
four ASC lines. iASC were culture until confluency at passage 3.
Three days before next confluency, we did not perform medium
change before its collection and freezing at -80°C. Factors were
measured in each supernatant in biological triplicates by using a
sensitive Luminex®-based detection method, targeting IL-1 beta (A):
IL-6; (B): CCL2; (C): CXCL5; (D): FGF; (E): VEGF; (F): Results are
presenting the average and standard deviation for three biological
replicates.
Figure 5: Measurement of MMPs in supernatants of four ASC lines.
iASC were culture until confluency at passage 3. Three days before
next confluency, we did not perform medium change before its
collection and freezing at -80°C. MMPs were measured in each
supernatant in biological triplicates by using a sensitive Luminex®-
based detection method.
Discussion
In this pilot and proof-of-principle study, we successfully derived
ASC lines from the fat of ischemic adults and expand them in vitro in
animal-free culture conditions. A more in-depth analysis (by
microarray and Luminex®-based arrays) suggests a robust secretoma in
favor of wound healing properties. Clinically speaking, iASC are good
candidates for ischemic wound healing, even if clinical experience in
humans remains very sparse in contrast to animal models [5]. Lee et al.
published a small pilot study using ASC in 15 patients with critical
limb ischemia. They injected 3 × 108 ASC/ml at different points in
limb muscles and achieved improvement of ischemia in 67%, but there
were only three patients with diabetic foot ulcers. The authors
nevertheless demonstrated the feasibility of their therapeutic approach
[12]. Other authors tried the same. Gadelkarim et al. performed a
recent extensive literature review on ASC administered via scaffolds
and/or skin grafts into chronic wounds [13]. In their review, authors
injected different doses of ASC, ranging between 2 × 104 and 5 × 107
cells. Chronic ischemic wounds treated with ASC exhibited
significantly higher healing rates. However, as a major drawback in the
current literature, the majority of the wounds investigated were on
other regions; and nota bene not in the distal diabetic foot [14,15].
Wound healing involves multiple steps including (i) inflammation, (ii)
cell growth factor activity, (iii) angiogenesis (iv) tissue remodeling.
Inflammation is first required to attract locally neutrophils for the
phagocytosis of debris, pathogens and damaged tissue, in addition to
releasing signaling molecules that initiate the proliferative phase of
wound healing. One of the key elements for this step is macrophages
that release potent pro-inflammatory cytokines such as IL-1, IL-6 and
IL-8 (CXCL-8). Via production of these three cytokines, iASC could
contribute to enhance the inflammatory step of healing. In accordance
with those properties, iASC could enhance macrophage activity
through CSF-1 (M-CSF). CSF-1 is a hematopoietic growth factor that
is involved in the proliferation, differentiation, and survival of
macrophages, also increasing their phagocytic and chemotactic
activity. Stimulated on site by hypoxia, they produce angiogenic and
cell growth factors to re-epithelialize the wound, create granulation
tissue and lay down a new extracellular matrix. Neovascularization
follows inflammation during the healing process. This process is
concomitant with fibroblasts proliferation when endothelial cells
migrate to the area of the wound during inflammation. Macrophages
consequently switch from a pro-inflammatory to a healing mode
through secretion of chemokines and VEGF. Chemokines attract
adjacent endothelial cells that respond by forming capillaries and new
vessels. To ensure this vascularization, endothelial cells
need collagenases such as MMP to degrade fibrin and part of the
extracellular matrix. iASC produces angiogenic factors such as VEGF,
ANGPTL-2, ANGPTL-4, and adrenomedullin. VEGF is a potent
angiogenic factor, whereas ANGPTL2 is a glycoprotein-promoting
inflammation protein, serving in tissue reconstruction and
angiogenesis [17-19]. ANGPTL4 harbors vasodilator properties
through NO production and is also a potent angiogenic factor [16,17].
Tissue remodeling suited for angiogenesis is also suggested to be
favored by iASC as the most abundant mRNA expression
corresponded to Matrix-Metallo-Proteinases (MMP), with a
predominance of MMP-1, 2, 3, 14, and 16. This not only suggests a
major role of ASC in subcutaneous tissue remodeling or angiogenesis
but equally reinforces their clinical interest.
Simultaneously with angiogenesis, fibroblasts must accumulate in
the site to become the main cell in the wound. Again, macrophage and
mast cells release FGFs and chemokines to activate fibroblasts from
adjacent tissues, this process being possible through environmental
MMPs [20,21]. The deposited fibroblastic connective tissue then forms
granulation tissue prior to collagen production for a new matrix.
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Granulation tissue consists of new blood vessels, fibroblasts,
inflammatory cells, endothelial cells, and the components of a new
extracellular matrix. FGFs, IFGs, PDGF, TGF-β, and fibronectin
stimulate fibroblasts proliferation, migration to the wound, and
production of the matrix. All of these factors are produced by iASC.
The family of Insulin Growth Factor Binding Proteins (IGFBP) was the
most represented in iASC, with notably the robust expression of
IGF2BP2, IGFBP3, IGFBP4, IGFBP6 and IGFBP7 (Figure 4A). IGFBPs
have several functions, including the promotion of Insulin-like Growth
Factors (IGF) transport and activity, the latter harboring growth-
promoting actions in many tissues of the body near the site of their
formation, by the way of paracrine and autocrine effects. A profile of
FGF expression shared between iASC was also observed, with the
expression of FGF-2, FGF-5, and FGF-7 (Figure 4B) [20-22].
Conclusion
In conclusion, ASC form ischemic patients show a secretome in
favor of healing promotion. These regenerative properties are
suggested to favor inflammation through the production of pro-
inflammatory chemokines and factors enhancing macrophages
activity. iASC also produces angiogenic factors, matrix remodeling
proteases, chemokines, and keratinocytes/fibroblast growth inductors
to help for later steps of healing. This pilot evaluation confirms the
feasibility of harvesting, amplifying autologous ASC from superficial
fat of ischemic patients ex vivo, as well as regenerative properties
compatible with cell therapy of ischemic ulcers, including for the
diabetic foot.
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